The "Psoriatic Arthritis - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering.A notable advancement has been made within the Psoriatic Arthritis (PsA) therapeutic area, ...

The Food and Drug Administration (FDA) has expanded the approval of Bimzelx (bimekizumab-bkzx) to include 3 new indications.

The FDA cleared Bimzelx to treat adults with active psoriatic arthritis (PsA), active non-radiographic axial ...

With more than 300 patients in the trial, dubbed FOREMOST, 33.9% of those assigned to apremilast achieved minimal disease ...

Biopharmaceutical company UCB has received US Food and Drug Administration (FDA) approval for BIMZELX (bimekizumab-bkzx) to ...

USA: The results of the FOREMOST trial indicate that apremilast is effective for patients with early psoriatic arthritis (PsA ...

One in four participants in a European wide study aimed at detecting early signs of psoriasis showed signs of possible ...

The US Food and Drug Administration has approved bimekizumab -bkzx (Bimzelx; UCB) for adult patients with active psoriatic ...

UCB (UCBJY) (UCBJF) said it has received FDA approval for its drug Bimzelx for the treatment of active psoriatic arthritis, ...

Tremfya is a prescription drug used for psoriasis and psoriatic arthritis. Find out about possible interactions with alcohol, ...

Bimekizumab-bkzx (Bimzelx) is now FDA approved for 4 chronic immune-mediated inflammatory diseases: psoriatic arthritis, nonradiographic axial spondyloarthritis (axSpA), ankylosing spondylitis, and ...

SAN FRANCISCO, CA, UNITED STATES, September 23, 2024 /EINPresswire / -- Each year, the National Psoriasis Foundation (NPF) invites the community of ...